These findings suggest that β‐AR activation and phosphodiesterase 4 (PDE4) inhibition mitigate oAβ‐induced memory deficits, supporting enhanced cAMP signaling as a therapeutic target for early AD. This evidence concerns the gene ADRB2 and Alzheimer disease.